行情

RARE

RARE

Ultragenyx药业
NASDAQ

实时行情|Nasdaq Last Sale

43.00
+0.21
+0.49%
盘后: 43.00 0 0.00% 16:25 12/06 EST
开盘
43.07
昨收
42.79
最高
43.63
最低
42.50
成交量
39.80万
成交额
--
52周最高
74.50
52周最低
35.41
市值
24.84亿
市盈率(TTM)
-5.9467
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RARE 新闻

  • Ultragenyx Pharmaceutical (RARE) Investor Presentation - Slideshow
  • Seeking Alpha - Article.1天前
  • Astellas-Audentes Deal Likely to Ignite More Acquisitions
  • GuruFocus.com.1天前
  • Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?
  • Zacks.1天前
  • The Gene Therapy Names Moving On The Audentes Buyout Deal
  • Benzinga.3天前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

RARE 简况

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
展开

Webull提供Ultragenyx Pharmaceutical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。